Home

Jacques Lapointe

Academic title(s): 

Associate Professor

Contact Information
Email address: 
jacques.lapointe [at] mcgill.ca
Phone: 
514-934-1934
Location: 
McGill University Health Centre (MUHC - Glen) - Royal Victoria Hospital
Office: 
EM2.2212
Division: 
Urology
Hospital title: 
Scientist
Degree(s): 

MD, PhD

Awards, honours, and fellowships: 
  • Governor General’s Academic Medal
  • Canadian Institutes of Health Research Postdoctoral Fellowship
  • The Scotiabank Rising Research Star Award
  • Chercheur Boursier (Junior 1 and 2), Fonds de Recherche du Québec-Santé (FRQS)
Current research: 
  • Prostate cancer functional genomics
  • Biomarkers
Clinical Interests: 

Prostate cancer

Language(s) spoken: 
English
French
Biography: 

Dr Lapointe completed his MD, residency in Family Medicine, and PhD in Physiology-Endocrinology at Université Laval (Québec, Canada). He received his postdoctoral training at Stanford University (California, USA) before joining the Division of Urology at McGill.

Selected publications: 

CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis.

Mehra C, Chung JH, He Y, Lara-Márquez M, Goyette MA, Boufaied N, Barrès V, Ouellet V, Guérard KP, Delliaux C, Saad F, Lapointe J, Côté JF, Labbé DP, Lamarche-Vane N. Commun Biol. 2021 Sep 7;4(1):1042.

Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.

Ebrahimizadeh W, Guérard KP, Rouzbeh S, Bramhecha YM, Scarlata E, Brimo F, Patel PG, Jamaspishvili T, Aprikian AG, Berman D, Bartlett JMS, Chevalier S, Lapointe J. J Mol Diagn. 2020 Oct;22(10):1246-1263.

A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.

Patel PG, Wessel T, Kawashima A, Okello JBA, Jamaspishvili T, Guérard KP, Lee L, Lee AY, How NE, Dion D, Scarlata E, Jackson CL, Boursalie S, Sack T, Dunn R, Moussa M, Mackie/ K, Ellis A, Marra E, Chin J, Siddiqui K, Hetou K, Pickard LA, Arthur-Hayward V, Bauman G, Chevalier S, Brimo F, Boutros PC, Lapointe J, Bartlett JMS, Gooding RJ, Berman DM. Prostate. 2019 Oct;79(14):1705-1714.

The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.

Bramhecha YM, Rouzbeh S, Guérard KP, Scarlata E, Brimo F, Chevalier S, Hamel L, Aprikian AG, Lapointe J. Mod Pathol. 2019 Jan;32(1):128-138.

Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention.

Bramhecha YM, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, Hamel L, Dragomir A, Aprikian AG, Lapointe J. Mol Cancer Res. 2018 Jan;16(1):115-123.

Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.

Patel PG, Selvarajah S, Boursalie S, How NE, Ejdelman J, Guerard KP, Bartlett JM, Lapointe J, Park PC, Okello JB, Berman DM. J Vis Exp. 2016 Aug 21;(114):54299.

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, Giguère V. Genes Dev. 2017 Jun 15;31(12):1228-1242.

The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression.

Choucair KA, Guérard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J. Transl Oncol. 2012 Dec;5(6):453-60.

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.

Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. BMC Cancer. 2012 Nov 22;12:543.

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.

Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. Cancer Res. 2007 Sep 15;67(18):8504-10.

Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6.

Follow us on:

Back to top